Comparative Pharmacology
Head-to-head clinical analysis: ALFENTANIL versus SYNALGOS DC A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFENTANIL versus SYNALGOS DC A.
ALFENTANIL vs SYNALGOS-DC-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
SYNALGOS-DC-A contains dihydrocodeine, which is a semisynthetic opioid agonist; aspirin, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes; and caffeine, a central nervous system stimulant. Dihydrocodeine binds to mu-opioid receptors in the central nervous system to produce analgesia. Aspirin irreversibly acetylates COX-1 and COX-2, reducing prostaglandin synthesis. Caffeine enhances analgesia via adenosine receptor antagonism and possibly by increasing drug absorption.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
1-2 capsules orally every 4-6 hours as needed for pain; each capsule contains dihydrocodeine bitartrate 16 mg, acetaminophen 356.4 mg, and caffeine 30 mg.
Clinical Note
moderateAlfentanil + Torasemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide."
Clinical Note
moderateAlfentanil + Etacrynic acid
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Etacrynic acid."
Clinical Note
moderateAlfentanil + Furosemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Furosemide."
Clinical Note
moderateAlfentanil + Bumetanide
None Documented
None Documented
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Propoxyphene: 6-12 hours; norpropoxyphene: 30-36 hours; clinical context: prolonged with hepatic impairment, age >60 years, and renal dysfunction; accumulation of norpropoxyphene may cause cardiotoxicity
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Renal: ~70-80% as free and conjugated propoxyphene; norpropoxyphene is renally eliminated; biliary: 10-20%; fecal: <10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Bumetanide."